Lifeline Biotechnologies Inc (LLBO)

[E-7-2]

Better than news, I found the Cyrcadia Breast Monitor (CBM) study which indicates that an independent study of 174 women will be completed December 2020. It started in September 2020. The earlier study indicated that the CBM was equal to current modalities for the detection of breast cancer.

"The results from the initial studies indicate that the CBM may be valuable for breast health monitoring under physician supervision for the confirmation of any abnormal changes."

Look for yourself: pubmed.ncbi.nlm.nih.gov

This at least provides us a finish line for FDA review/approval.

IMO we will hear a result from the FDA in the first quarter of 2021 in not earlier. Possible buyout upon FDA approval.